For the final part of their roundtable conversation, Roger Li, MD, Vitaly Margulis, MD, Kyle Rose, MD, and Paul Crispen, MD, share their insights on risk assessment, the impact of molecular biomarkers, and customized treatment strategies for high-risk non-muscle-invasive bladder cancer. This discussion sheds light on the hurdles of aligning clinical trials with real-world practice, explores the promise of precision-targeted therapies, and examines the evolving landscape of personalized medicine in NMIBC management.

#bladdercancer #cancer #cancerresearch #urology #healthcare #oncology

свернуть